NASDAQ:STRO

Sutro Biopharma (STRO) Stock Forecast, Price & News

$4.50

+0.01 (+0.22%)

(As of 11:57 AM ET)

Compare

Today's Range: $4.34
▼
$4.53
50-Day Range: $4.25
▼
$5.88
52-Week Range: $3.33
▼
$8.72

Volume: 84,433 shs
Average Volume: 482,007 shs
Market Capitalization: $270.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.33

Sutro Biopharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 285.2% Upside
$17.33 Price Target
Short Interest: Bearish
5.15% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: 0.22
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.87) to ($2.53) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

1027th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

159th out of 330 stocks

3.4

Analyst's Opinion

Consensus Rating
Sutro Biopharma has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.33, Sutro Biopharma has a forecasted upside of 285.2% from its current price of $4.50.
Amount of Analyst Coverage
Sutro Biopharma has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.15% of the outstanding shares of Sutro Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Sutro Biopharma has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Sutro Biopharma has recently increased by 4.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Sutro Biopharma does not currently pay a dividend.
Dividend Growth
Sutro Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sutro Biopharma is -0.70.

1.8

News and Social Media Coverage

News Sentiment
Sutro Biopharma has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for STRO on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.40% of the stock of Sutro Biopharma is held by insiders.
Percentage Held by Institutions
87.64% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sutro Biopharma are expected to grow in the coming year, from ($2.87) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sutro Biopharma is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sutro Biopharma is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sutro Biopharma has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

May 31, 2023 | finance.yahoo.com

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 28, 2023 | finance.yahoo.com

Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 51% over the last three years

June 1, 2023 | Edge On The Street (Ad)

AI Getting Close to Thinking Like Humans

Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.

May 25, 2023 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $17.33 Consensus Price Target from Analysts

May 20, 2023 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Expected to Post Q2 2023 Earnings of ($0.73) Per Share

May 17, 2023 | msn.com

JMP Securities Reiterates Sutro Biopharma (STRO) Market Outperform Recommendation

May 17, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Sutro Biopharma, Inc. Lowered by Analyst (NASDAQ:STRO)

May 16, 2023 | benzinga.com

Sutro Biopharma Stock (NASDAQ:STRO), Insider Trading Activity

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

May 16, 2023 | msn.com

HC Wainwright & Co. Reiterates Sutro Biopharma (STRO) Buy Recommendation

May 15, 2023 | finance.yahoo.com

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 4, 2023 | finance.yahoo.com

Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?

May 3, 2023 | msn.com

Sutro, Mersana jump after Immunogen data for ovarian cancer therapy

May 1, 2023 | finance.yahoo.com

Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

April 30, 2023 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Moderate Buy" by Analysts

April 27, 2023 | finance.yahoo.com

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

April 18, 2023 | finance.yahoo.com

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

April 17, 2023 | finance.yahoo.com

Investors Don't See Light At End Of Sutro Biopharma, Inc.'s (NASDAQ:STRO) Tunnel

April 12, 2023 | americanbankingnews.com

Coherus BioSciences (NASDAQ:CHRS) versus Sutro Biopharma (NASDAQ:STRO) Head to Head Review

April 5, 2023 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Moderate Buy" from Brokerages

April 3, 2023 | markets.businessinsider.com

JMP Securities Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

April 3, 2023 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $17.00 by Analysts at JMP Securities

April 1, 2023 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $16.00 at HC Wainwright

April 1, 2023 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Receives "Outperform" Rating from Wedbush

April 1, 2023 | seekingalpha.com

STRO Sutro Biopharma, Inc.

March 31, 2023 | markets.businessinsider.com

Where Sutro Biopharma Stands With Analysts

March 30, 2023 | finance.yahoo.com

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

See More Headlines

STRO Price History

30 days | 90 days | 365 days | Advanced Chart

STRO Company Calendar

Last Earnings: 11/10/2021
Today: 6/01/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:STRO
CUSIP: N/A
CIK: 1382101
Web: www.sutrobio.com
Phone: (650) 392-8412
Fax: N/A
Employees: 224
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.33
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +286.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,200,000.00
Net Margins: -174.57%
Pretax Margin: -170.69%
Return on Equity: -59.26%
Return on Assets: -32.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.11
Quick Ratio: 5.11

Sales & Book Value

Annual Sales: $67.77 million
Price / Sales: 3.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.08 per share
Price / Book: 1.46

Miscellaneous

Outstanding Shares: 60,190,000
Free Float: 55,738,000
Market Cap: $270.25 million
Optionable: Not Optionable
Beta: 0.88

Key Executives

William J. Newell
President, Chief Executive Officer & Director

Edward C. Albini
Chief Financial Officer & Secretary

Trevor Hallam
Chief Scientific Officer & President-Research

Shabbir T. Anik
Chief Technical Operations Officer

Craig Berman
Vice President-Clinical Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

STRO Stock - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares.
View STRO analyst ratings or view top-rated stocks.
What is Sutro Biopharma's stock price forecast for 2023?: 6 Wall Street analysts have issued twelve-month target prices for Sutro Biopharma's stock. Their STRO share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 286.0% from the stock's current price.
View analysts price targets for STRO or view top-rated stocks among Wall Street analysts.
How have STRO shares performed in 2023?: Sutro Biopharma's stock was trading at $8.08 at the start of the year. Since then, STRO shares have decreased by 44.4% and is now trading at $4.49.
View the best growth stocks for 2023 here.
When is Sutro Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our STRO earnings forecast.
How were Sutro Biopharma's earnings last quarter?: Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.02. The firm earned $8.52 million during the quarter, compared to analysts' expectations of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 59.26% and a negative net margin of 174.57%.
What ETFs hold Sutro Biopharma's stock?: ETFs with the largest weight of Sutro Biopharma (NASDAQ:STRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Biotechnology ETF (IBB),
What is William J. Newell's approval rating as Sutro Biopharma's CEO?: 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sutro Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?: (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is Sutro Biopharma's stock symbol?: Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."
Who are Sutro Biopharma's major shareholders?: Sutro Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.45%), BlackRock Inc. (8.34%), Rubric Capital Management LP (7.24%), State Street Corp (4.86%), Candriam S.C.A. (3.09%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends.
How do I buy shares of Sutro Biopharma?: Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sutro Biopharma's stock price today?: One share of STRO stock can currently be purchased for approximately $4.49.
How much money does Sutro Biopharma make?: Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $270.25 million and generates $67.77 million in revenue each year. The company earns $-119,200,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.
How many employees does Sutro Biopharma have?: The company employs 224 workers across the globe.
How can I contact Sutro Biopharma?: Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial